David Warshal

4.1k total citations
39 papers, 973 citations indexed

About

David Warshal is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, David Warshal has authored 39 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Reproductive Medicine, 17 papers in Obstetrics and Gynecology and 11 papers in Oncology. Recurrent topics in David Warshal's work include Ovarian cancer diagnosis and treatment (17 papers), Endometrial and Cervical Cancer Treatments (16 papers) and Uterine Myomas and Treatments (7 papers). David Warshal is often cited by papers focused on Ovarian cancer diagnosis and treatment (17 papers), Endometrial and Cervical Cancer Treatments (16 papers) and Uterine Myomas and Treatments (7 papers). David Warshal collaborates with scholars based in United States, Canada and South Korea. David Warshal's co-authors include John A. Blessing, Peter G. Rose, Paul DiSilvestro, Norman D. Rosenblum, Enrique Hernández, Mitchell I. Edelson, J. Andrew Carlson, Harrison Ball, Sharon L. Manne and David S. Miller and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and American Journal of Obstetrics and Gynecology.

In The Last Decade

David Warshal

36 papers receiving 954 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Warshal United States	14	439	427	315	176	141	39	973
Peter Grant Australia	21	517 1.2×	359 0.8×	266 0.8×	359 2.0×	208 1.5×	58	1.2k
Amy Bregar United States	16	463 1.1×	424 1.0×	245 0.8×	253 1.4×	97 0.7×	56	1.2k
Thomas W. Jobling Australia	18	303 0.7×	293 0.7×	182 0.6×	194 1.1×	214 1.5×	40	929
Mitchell I. Edelson United States	17	788 1.8×	440 1.0×	450 1.4×	392 2.2×	408 2.9×	42	1.8k
Amy Finch Canada	18	957 2.2×	276 0.6×	333 1.1×	72 0.4×	198 1.4×	29	1.6k
Hoa N. Nguyen United States	16	386 0.9×	369 0.9×	185 0.6×	212 1.2×	121 0.9×	37	866
E.B.L. van Dorst Netherlands	12	402 0.9×	126 0.3×	282 0.9×	108 0.6×	104 0.7×	24	1.0k
M. Heywood Canada	18	1.0k 2.4×	528 1.2×	440 1.4×	529 3.0×	111 0.8×	26	1.5k
Lee-may Chen United States	21	409 0.9×	294 0.7×	803 2.5×	203 1.2×	165 1.2×	41	1.6k
Michaela Onstad United States	10	145 0.3×	239 0.6×	304 1.0×	90 0.5×	158 1.1×	24	736

Countries citing papers authored by David Warshal

Since Specialization

Citations

This map shows the geographic impact of David Warshal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Warshal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Warshal more than expected).

Fields of papers citing papers by David Warshal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Warshal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Warshal. The network helps show where David Warshal may publish in the future.

Co-authorship network of co-authors of David Warshal

This figure shows the co-authorship network connecting the top 25 collaborators of David Warshal. A scholar is included among the top collaborators of David Warshal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Warshal. David Warshal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carter, Jeanne, Helen Huang, Bradley J. Monk, et al.. (2025). Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278). Gynecologic Oncology. 195. 50–58. 1 indexed citations

Katz, C., Kōtaro Murakami, Sudipto Ganguly, et al.. (2024). 173P NRF2 levels in high grade serous ovarian cancer: Characterization and treatment. ESMO Open. 9. 103910–103910.

Avilés, Diego, et al.. (2023). The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome. Biomolecules. 13(7). 1066–1066. 5 indexed citations

Powell, Matthew A., Virginia L. Filiaci, Martee L. Hensley, et al.. (2022). Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal of Clinical Oncology. 40(9). 968–977. 47 indexed citations

McIntosh, Erin, et al.. (2017). Bilateral ovarian micrometastatic adenocarcinoma upon prophylactic oophorectomy concurrent with low anterior resection for rectal cancer. World Journal of Surgical Oncology. 15(1). 40–40. 7 indexed citations

Rose, Peter G., James Java, Mark A. Morgan, et al.. (2016). Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 143(3). 511–515. 7 indexed citations

McCourt, Carolyn K., Wei Deng, Don S. Dizon, et al.. (2016). A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 144(1). 101–106. 5 indexed citations

Alberts, David S., John A. Blessing, Lisa M. Landrum, et al.. (2012). Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology. 127(3). 451–455. 51 indexed citations

Tiersten, Amy, Michael W. Sill, Franco M. Muggia, et al.. (2010). A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: A feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 118(3). 303–307. 4 indexed citations

10.

Miller, Brigitte, John A. Blessing, Frederick B. Stehman, et al.. (2010). A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study. Gynecologic Oncology. 118(2). 139–144. 20 indexed citations

11.

Schilder, Russell J., John A. Blessing, Mark S. Shahin, et al.. (2010). A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial. International Journal of Gynecological Cancer. 20(7). 1137–1141. 11 indexed citations

12.

Farley, John, Kathleen M. Darcy, Chunqiao Tian, et al.. (2009). Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 113(3). 341–347. 28 indexed citations

13.

Kavanagh, J. J., Michael W. Sill, Pedro T. Ramírez, et al.. (2007). Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer. 18(3). 460–464. 10 indexed citations

14.

DiSilvestro, Paul, et al.. (2006). Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group. Gynecologic Oncology. 103(3). 1038–1042. 30 indexed citations

15.

Larijani, Ghassem E., et al.. (2005). Pain Evaluation in Patients Receiving Intravenous Patient‐Controlled Analgesia After Surgery. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(9). 1168–1173. 4 indexed citations

16.

Larijani, Ghassem E., Michael E. Goldberg, Irwin Gratz, & David Warshal. (2004). Analgesic and Hemodynamic Effects of a Single 7.5‐mg Intravenous Dose of Morphine in Patients with Moderate‐to‐Severe Postoperative Pain. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(12). 1675–1680. 11 indexed citations

17.

Fultz, Patrick J., William J. Hall, Ronald H. Gottlieb, et al.. (1999). Ovarian Cancer: Comparison of Observer Performance for Four Methods of Interpreting CT Scans. Radiology. 212(2). 401–410. 19 indexed citations

18.

Warshal, David, Patrick J. Fultz, Andrea E. Dawson, Giuseppe Del Priore, & Brent DuBeshter. (1996). Interstitial pregnancy complicated by rectal bleeding. American Journal of Obstetrics and Gynecology. 175(5). 1373–1375. 2 indexed citations

19.

Priore, Giuseppe Del, et al.. (1995). Adrenal Function Following High-Dose Steroids in Ovarian Cancer Patients. Gynecologic Oncology. 59(1). 102–104. 11 indexed citations

20.

Sherer, David, et al.. (1991). Recurrent mild abruptio placentae occurring immediately after repeated electroconvulsive therapy in pregnancy. American Journal of Obstetrics and Gynecology. 165(3). 652–653. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact